Leigh Syndrome - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The leigh syndrome market size is projected to be USD 7.73 billion in 2025, USD 8.28 billion in 2026, and reach USD 11.68 billion by 2031, growing at a CAGR of 7.12% from 2026 to 2031. This report is segmented by Genetic Etiology (nDNA, Mtdna, PDH, Coq10, Others), Treatment Type (Supportive, Vitamin/Cofactor, Gene/RNA, Mitochondrial Replacement, Others), Route (Oral, IV, Subcutaneous, ICV, Enteral), Care Setting (Tertiary Hospitals, Pediatric Neurology, Mito Centers, Specialty Clinics, Home Care), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Leigh Syndrome Market Trends and Insights

Increasing Genetic Testing and Earlier Diagnosis

Earlier genetic testing is a central near-term factor for the Leigh syndrome market because it changes the point at which patients can enter specialist care. The NCBI Genetic Test Registry listed 271 sequencing-based tests for Leigh syndrome spectrum from 32 laboratories worldwide in July 2025. The Global Patient Registry reported that it included more than 400 participants across 48 countries, showing the breadth of the patient identification effort. Earlier confirmation allows sponsors to identify people with defined mutations before trial enrollment begins. Thiogenesis structured its Phase 2a enrollment around confirmed genetic subtypes, which shows the practical value of these patient pools. The NAMDC, which is supported through the NIH Rare Diseases Clinical Research Network, provides a national structure that links diagnosis, specialist care, and research participation. More confirmed cases can also make the clinical needs of the Leigh syndrome market clearer to treatment centers and program sponsors.

Progress in Mitochondrial Targeted and Gene Therapies

Mitochondrial-targeted and gene therapies are changing the development outlook for the Leigh syndrome market. A 2026 Nature Biotechnology study corrected disease-associated mitochondrial variants in rat zygotes with engineered base editors and reported a 53.00% average restoration of wild-type alleles . A 2025 Brain study found that focused-ultrasound-assisted AAV9 delivery crossed the blood-brain barrier and improved survival, cardiac function, and brain function in Ndufs4 knockout mice. These findings address a major delivery barrier for therapies intended to reach the central nervous system. Taysha’s TSHA-104 program illustrates the mutation-specific approach for SURF1-associated Leigh syndrome and has received Rare Pediatric Disease and Orphan Drug designations. A refined AAV9 vector design reported in 2025 maintained efficacy in rat models while reducing cytotoxicity, which may strengthen safety planning before a future resubmission.

Genetic and Phenotypic Heterogeneity

Genetic and phenotypic heterogeneity limit the scale available to any single program in the Leigh syndrome market. Leigh syndrome can arise from more than 100 genes across mitochondrial and nuclear genomes. The same MT-ATP6 m.9176T>C variant can produce severe Leigh syndrome or the milder NARP phenotype, depending on heteroplasmy load. A program focused on SURF1-related disease may reach only 10.00% to 15.00% of patients, while MT-ATP6 programs serve a separate group. The SIMPATHIC trial is restricted to MT-ATP6-related disease and shows how genetic selection narrows each study population. This division complicates trial recruitment and reduces the revenue pool attached to a mutation-specific approval.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Patient Registries and Trial Ready Cohorts
• Expansion of Rare Mitochondrial Disease Research Funding
• High Cost of Rare Disease Drug Development

Segment Analysis

Nuclear DNA-Associated Leigh Syndrome accounted for 58.24% of the Leigh syndrome market size by genetic etiology in 2025. Nuclear variants, including SURF1, NDUFAF6, and PDHA1, are prevalent in confirmed cases and have clearer molecular targets. The Global Patient Registry found that 64.00% of enrolled participants had nuclear DNA mutations. SURF1 represented 72.00% of the nuclear DNA mutation cohort in that registry. Mitochondrial DNA-Associated Leigh Syndrome is the second-largest category and is associated largely with MT-ATP6 and MT-ND subunit variants.

Coenzyme Q10 Deficiency is forecast to grow at an 11.42% CAGR through 2031. Improved sequencing can identify biosynthesis pathway mutations with greater precision. CoQ10 supplementation and next-generation analogs provide a clinically tractable route for this subtype. A registered drug-repurposing study is using iPSC-derived neuronal models to screen FDA- and EMA-approved compounds across nuclear and mitochondrial DNA-associated subtypes. PDH Deficiency remains a defined but underserved group that requires metabolic management, ketogenic diets, and thiamine supplementation.

Supportive & Symptomatic Therapy accounted for 46.37% of the Leigh syndrome market in 2025. This category reflects the continuing use of intensive care, mechanical ventilation, seizure management, and nutritional support. These services remain essential because approved disease-modifying therapies are not available. Vitamin and cofactor supplementation and antioxidant therapy form the second-largest current spending block. Riboflavin, CoQ10, thiamine, and alpha-lipoic acid have long been used in clinical management.

Gene & RNA-Based Therapies are forecast to grow at a 24.86% CAGR through 2031. AAV9 delivery programs, mitochondrial base editing, and mitoTALEN correction tools support this forecast. Improved vector design is intended to preserve efficacy while lowering cytotoxicity in preclinical models. Mitochondrial Replacement & Advanced Therapies remain early in commercial development. Their clinical progress will depend on adequate safety evidence and on the ability to administer treatment within specialist pediatric services.

Complete Report Scope:

• By Genetic Etiology
  • Nuclear DNA (nDNA)-Associated Leigh Syndrome
  • Mitochondrial DNA (mtDNA)-Associated Leigh Syndrome
  • Pyruvate Dehydrogenase Complex (PDH) Deficiency
  • Coenzyme Q10 Deficiency
  • Other Genetic Subtypes
• By Treatment Type
  • Supportive & Symptomatic Therapy
  • Vitamin & Cofactor Supplementation
  • Antioxidant Therapy
  • Gene & RNA-Based Therapies
  • Mitochondrial Replacement & Advanced Therapies
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Intracerebroventricular
  • Enteral Administration
• By Care Setting
  • Tertiary Hospitals
  • Pediatric Neurology Centers
  • Mitochondrial Disease Centers of Excellence
  • Specialty Clinics
  • Rehabilitation Centers
  • Home Healthcare
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.28% of the Leigh syndrome market in 2025. The region benefits from rare-disease pathways, specialist centers, and structured research networks. The NAMDC supports connections between diagnosed patients, clinical research sites, and specialist services through the NIH Rare Diseases Clinical Research Network. Canada supports development activity through Thiogenesis, while Mexico has earlier-stage specialist neurological care access. These features give the North American Leigh syndrome market a more established clinical infrastructure than many other regions.

Europe is the second-largest regional presence in the Leigh syndrome market. Khondrion dosed the first patient in the pivotal KHENERFIN Phase 3 study in April 2026. The EMA granted orphan designation to sonlicromanol for inherited mitochondrial oxidative phosphorylation defects in July 2025. The United Kingdom, France, Italy, and Spain add coordinated referral capability through specialist mitochondrial and rare metabolic centers.

Asia-Pacific is forecast to grow at a 15.38% CAGR through 2031. Japan completed a Phase 3 trial of SPP-004, which showed stabilization or improvement in central nervous system symptoms in 50.00% of enrolled patients. China offers a substantial diagnostic opportunity, as Leigh syndrome represented 28.00% of genetically confirmed pediatric mitochondrial cases in a 2025 multicenter cohort. The same study reported a median onset of 1.15 years for nuclear DNA subtypes and 5.42 years for mitochondrial DNA subtypes. India, South Korea, and Australia are building rare-disease research capacity and genomics laboratory networks.

List of Companies Covered in this Report:

• Abliva AB
• Aclarion
• Biogen
• BridgeBio Pharma
• Daiichi Sankyo
• Dainippon Sumitomo Pharma Co., Ltd.
• Edison Pharmaceuticals, Inc.
• GenSight Biologics S.A.
• Ionis Pharmaceuticals
• Khondrion B.V.
• Minovia Therapeutics, Inc.
• OMEICOS Therapeutics GmbH
• PTC Therapeutics, Inc.
• Sarepta Therapeutics
• Stealth BioTherapeutics Corp.
• Takeda Pharmaceuticals
• Taysha Gene Therapies, Inc.
• Thiogenesis Therapeutics, Inc.
• VAKS Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support